论文部分内容阅读
目的：研究子宫内膜癌ｂｃｌ－２癌基因的表达及其临床意义。方法：采用免疫组化ＡＢＣ法检测增生期、分泌期、单纯型增生、复合型增生及不典型增生子宫内膜共２６份，子宫内膜癌４９例的ｂｃｌ－２癌基因蛋白表达及雌、孕激素受体（ＥＲ、ＰＲ）的表达。结果：正常增生期子宫内膜、增生的子宫内膜存在ｂｃｌ－２的表达，与ＥＲ相关，分泌期子宫内膜ｂｃｌ－２表达下降；４９例子宫内膜癌中２６例ｂｃｌ－２表达阳性，占５３％，２９例ＥＲ表达阳性，占５９％，２５例ＰＲ表达阳性，占５１％。７２％ｂｃｌ－２表达阳性者ＥＲ阳性，７５％ｂｃｌ－２表达阴性者ＥＲ阴性（Ｐ＜０．０１）。６８％ｂｃｌ－２表达阳性者ＰＲ阳性，６２％ｂｃｌ－２阴性者ＰＲ阴性（Ｐ＜０．０５）。子宫内膜癌Ｇ１、Ｇ２级ｂｃｌ－２的表达率为６６％，显著高于Ｇ３级者（２１％）（Ｐ＜０．０５）。ｂｃｌ－２的表达与肌层浸润、手术分期无关，ｂｃｌ－２表达阳性及阴性者生存率统计差异无显著性。结论：子宫内膜ｂｃｌ－２的持续性表达与卵巢激素相互作用可能在子宫内膜癌发生、发展中起作用
Objective: To study the expression of bcl-2 oncogene in endometrial carcinoma and its clinical significance. METHODS: Immunohistochemical ABC method was used to detect the expression of bcl-2 oncoprotein in 26 cases of proliferative phase, secretory phase, simple hyperplasia, complex hyperplasia and atypical hyperplasia endometrium and 49 cases of endometrial carcinoma. Progesterone receptor (ER, PR) expression. Results: The expression of bcl-2 was found in the endometrium and proliferative endometrium of normal proliferative phase, which was related to ER. The expression of bcl-2 in endometrium of secretory phase was decreased. The expression of bcl-2 was positive in 26 cases of endometrial carcinoma. , accounting for 53%, 29 cases of ER expression positive, accounting for 59%, 25 cases of PR positive expression, accounting for 51%. 72% of patients with positive bcl-2 expression were positive for ER, 75% of patients with negative bcl-2 expression were negative for ER (P<0.01). PR positive was found in 68% of patients with bcl-2 expression, and PR was negative in 62% of patients with negative bcl-2 (P<0.05). The expression of bcl-2 in G1 and G2 of endometrial carcinoma was 66%, which was significantly higher than that of G3 (21%) (P<0.05). The expression of bcl-2 was not related to myometrial invasion and surgical staging. There was no statistical difference in the survival rate of positive bcl-2 and negative bcl-2. Conclusion: The persistent expression of bcl-2 in endometrial and ovarian hormone interaction may play a role in the occurrence and development of endometrial carcinoma.